Global NASH Treatment Market Grows as New Therapies Take Center Stage

Global NASH Treatment Market Growth: A New Era of Therapies

The global landscape for Non-Alcoholic Steatohepatitis (NASH) treatment is witnessing remarkable changes as innovative therapies pave the way for better patient management. According to Strategic Market Research, the NASH treatment market, valued at USD 8.75 billion in 2025, is anticipated to soar to USD 46.87 billion by 2032. This growth signifies a compound annual growth rate (CAGR) of 27.1% from 2026 to 2032, indicating a vibrant expansion fueled by the emergence of new treatment options and a deeper understanding of the disease.

Understanding NASH and MASH

Traditionally referred to as NASH, more recent terminology has introduced metabolic dysfunction-associated steatohepatitis (MASH), although NASH remains prevalent in clinical discussions, clinical trials, and patient records. This shift in terminology reflects the broader understanding of the disease and its relationship to metabolic disorders. While awareness of fatty liver disease has grown, the challenge lies in identifying and treating the right patient population, specifically those with noncirrhotic MASH or NASH and moderate-to-advanced fibrosis—the focus of approved treatments.

Expanding Patient Populations

The screening potential within the metabolic-associated steatotic liver disease community is vast. With approximately 1.3 billion individuals diagnosed worldwide as of 2023, this number is expected to reach around 1.8 billion by 2050. However, the actual commercial treatment pool remains smaller due to existing treatments targeting specific fibrosis stages. Research indicates that around 6 to 8 million Americans have NASH with moderate-to-advanced liver scarring, while projections suggest the number of affected adults will steadily increase over the years.

Healthcare systems are evolving to implement blood tests, elastography, and other imaging techniques to help assess the fibrosis stage in patients, enhancing the identification of those who qualify for pharmacological treatment.

Trailblazers in NASH Treatment: Rezdiffra and Wegovy

Madrigal Pharmaceuticals has pioneered the development of the first dedicated prescription pathway for NASH with the FDA's approval of Rezdiffra in March 2024. This groundbreaking therapy is designed to offer once-daily oral dosing, positioning it as a practical long-term treatment. However, the success of Rezdiffra hinges not only on clinical efficacy but also on establishing reliable referral pathways and garnering payer acceptance.

Rezdiffra's clinical trials have demonstrated positive outcomes, such as resolution of NASH in a significant portion of participants. As a first mover in this market, Madrigal enjoys an advantage in raising awareness among specialists and creating treatment pathways.

Conversely, Wegovy, approved by the FDA in August 2025 for patients with MASH, stands out for its previous success in obesity and diabetes management. This approval alters the competitive dynamics of the market by providing a multifaceted approach to treating NASH, integrating weight management and addressing cardiometabolic risks.

Overcoming Diagnostic Challenges

Despite innovative treatments, diagnosing NASH remains a key challenge, with estimates suggesting diagnosis rates around 10%. Many patients at high risk remain within primary care without a confirmed fibrosis status, complicating treatment pathways. To bridge this gap, various screening tools such as FIB-4 scoring and elastography are critical to identifying those who meet treatment criteria.

Ongoing Developments and Future Outlook

Investment in NASH drug development continues despite the introduction of new therapies. The competitive landscape is evolving rapidly with the entry of drugs like Eli Lilly's tirzepatide and others currently in late-stage trials. The future may see a segmented market with a combination of oral therapies, injectable options, and innovative treatment regimens tailored to different patient needs.

North America currently leads this market, bolstered by established drug approvals and healthcare infrastructure that supports treatment accessibility. However, Europe and Asia are also progressing on distinct paths contingent on regulatory approvals and access strategies. In this ever-evolving environment, the ability to effectively identify, treat, and monitor patients will be pivotal for companies aiming for market leadership in this burgeoning sector.

In conclusion, the NASH treatment market is on the brink of significant transformation. With promising new therapies and a focus on targeted patient identification and treatment pathways, the coming years will be crucial in reshaping how NASH is managed clinically. Ensuring that the high-risk patient population is accurately diagnosed and treated will determine the success of these innovative therapies in achieving better patient outcomes.